Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut Syndrome: A randomizedcontrolled trial
Not Applicable
- Conditions
- Health Condition 1: G404- Other generalized epilepsy and epileptic syndromes
- Registration Number
- CTRI/2022/12/048517
- Lead Sponsor
- Dr Jayantee Kalita Principal Investigator
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children aged 2 to 18 years having LGS who are using 2-5 antiepileptic drugs (AED) for 1month will be eligible for enrolment.
Exclusion Criteria
Progressive cognitive or neurological deficit, known degenerative neurological disease or metabolic disease,hemi-clonic seizures in the first year of life, only clusters of drop seizure, visual loss, hepatic disease, and if concomitant ketogenic diet, cannabidiol, fenfluramine use at the time of enrolment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method